



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 18 Sep 2017 (#34)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries cdevries@sun.ac.za) to inform of your intent to apply.

Timelines: Confirm your intent to apply **as soon as possible, but not later than 30 days before the submission date**. All final documents **MUST reach the RGMO seven (7) workdays before NIH application due date**. The application will be submitted **four (4) workdays before the application due date**.

Important Notice

- [NIH's Certificates of Confidentiality Policy Enhances Confidentiality of Participants Enrolled in Clinical Research Studies](#)
- [NIH Applications Must Be Complete and Compliant With NIH Policy and Application Instructions At Time Of Submission \(NOT-OD-17-105\)](#)
- [Trans-NIH Strategic Plan for Research on Womens Health \(NOT-OD-17-108\)](#)
- [Continuing to Clarify the NIH Definition of a Clinical Trial](#)
- [NIH's Next Generation Researchers Policy Now Posted](#)
- [Data On Trends According to Career Stage](#)
- [Spreading the Word About Policies Impacting Human Subjects Research and Clinical Trials](#)

1. Next Generation Multipurpose Prevention Technologies (NGM). Clinical Trial Optional

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-17-028\)](#)

Type: R61/R33

Application Due Date: March 19, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative multipurpose prevention technologies (MPT) with rheological/biophysical properties and product user perceptions compatible with current long-acting reversible contraceptive (LARC) strategies (look, feel, effectiveness, safety and duration of action) for the dual purpose of preventing pregnancy and HIV infection in women. MPTs proposed for development must be dual indication and prevent pregnancy and HIV infection and have drug delivery systems (DDS) capable with sustained/extended release of both drugs. MPTs proposed for development must use a licensed contraceptive. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires submission of a pre-IND application to the FDA.

Budget: Issuing IC and partner components intend to commit \$4.1 million in FY 2019 to fund 2-3 awards. Application budgets are limited to \$800,000 in direct costs per year for the R61 award phase and \$1,600,000 in direct costs per year for the R33 award phase. The total project period for an application submitted in response to this FOA cannot exceed five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

2. Repurposing Target-Based Pharmaceutical Libraries for Discovery of Therapeutics against Eukaryotic Pathogens

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-17-036\)](#)

Type: R21/R33

Application Due Date: January 12, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support screening of target-based pharmaceutical libraries to identify candidate therapeutics against select eukaryotic pathogens and subsequent preclinical development activities.

Budget: NIAID intends to commit \$2.5M in FY 2019 to fund 10-15 awards. Application budgets are limited to \$275,000 in direct costs over the two-year project period for the R21 phase, with a maximum of \$200,000 in direct costs allowed in any single year. The R33 award phase is limited to \$300,000 in direct costs per year. The total project period cannot exceed five years. Applicants may request up to two years of support for the R21 phase and up to 3 years of support for the R33 phase. The NIAID anticipates approximately 50% of the funded R21 phase awards will transition to the R33 award.

3. Exploiting HIV and/or Host Genomic Information to Understand HIV Compartments or Reactivation in Individuals with Substance Use Disorders

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-DA-18-016\)](#)

Type: R61/R33

Application Due Date: December 13, 2017. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This initiative will support exploratory projects that exploit HIV or host genomic or nucleomic information to understand HIV latency in individuals with substance use disorders (SUDs).

Budget: NIDA intends to commit \$2 million dollars in FY2018 to fund 3-4 awards. Application budgets are limited to \$650,000 direct costs and must reflect the actual needs of the proposed project. Budget periods are limited to no more than three years for the R61 phase and no more than two years for the R33 phase.

4. Comparative Genomics Research Program - Clinical Trial Not Allowed

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-17-482\)](#)

Type: R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: National Human Genome Research Institute (NHGRI) invites applications for research developing comparative approaches that can be used to understand genome structure and function and the relationship between genomic features and phenotypes. This program supports studies that enable the use of a diverse array of species to advance our ability to understand basic biological processes related to human health and disease, as well as studies that develop novel analytical tools and resources for the comparative genomics research community.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years, but given how quickly the field is evolving, in order to ensure that the research is addressing the most current issues, many projects that are funded will be no more than 3 years in duration.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: [Dr Christa Coetsee](#) • Tel: 9838 • Email: cdevries@sun.ac.za